SFTPD and idiopathic pulmonary fibrosis: Predictive biomarkers have been evaluated for identification and assessment of disease progression (DP) in patients with IPF who were enrolled in phase 3 clinical trials of antifibrotic agents [12, 13], and baseline surfactant protein D was the only biomarker predicting the response to antifibrotics [12].